BioMarin Advances Amicus Integration and VOXZOGO Revenue Growth
BioMarin Pharmaceutical is progressing with the integration of Amicus Therapeutics, aiming to achieve $200 million in annual non-GAAP cost savings. Most synergies are expected by 2027, with full realization anticipated in 2028. The company also highlighted its rare-disease drug VOXZOGO nearing a revenue milestone of approximately $1 billion this year despite U.S. competition. BioMarin's CEO emphasized the integration is primarily aimed at accelerating revenue from Amicus' products GALAFOLD and POMBILITI + OPFOLDA, with peak sales projected to reach around $1.4 billion for GALAFOLD and $1.2 billion for POMBILITI by the mid-2030s. The company is also focusing on improving patient access and geographic expansion. With improved cash flow from synergies, BioMarin expects to reduce leverage below 2.5 times by mid-2027 and regain capacity for deals up to $6 billion by 2028.
Tickers: $BMRN
Topics: Biotech Mergers Cost Savings Pharmaceuticals Revenue Growth